CD274 and gastric cancer: Notably in the phase II trial KEYNOTE-059 exploring the efficacy of pembrolizumab as the third line of treatment of gastric cancer, an ORR of 22.7% vs. 16.4% was observed in a PD-L1-positive population compared to a negative one, although PD-L1-negative tumors still responded [52].